storage temp. : ?20°Cform : lyophilized powder

storage temp. : 20°Cform : lyophilized powder

We are pleased to announce that BIODESIGN International, OEM Concepts, Inc., and Viral Antigens, Inc. are now product brands within Meridian Life Science, Inc. (MLS). A new brand, Meridian Biologics, represents our R&D and manufacturing service for biopharmaceuticals.MLS will continue delivering all products currently available while developing new innovative solutions for your future needs. Our goal is to continue to earn your trust as a quality supplier of critical assay reagents, antigens, antibodies, biologicals, and contract R&D and manufacturing services. Visit our website or contact our brand representatives.www.meridianlifescience.com About Meridian Life ScienceMeridian Life Science, Inc. currently focuses on the development, manufacture, sale, and distribution of bulk antigens and reagents used by researchers and other diagnostic companies, as well as the contract manufacturing of proteins and other biologicals used by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.Growth strategies for Meridian Life Science include:(i) developing new product applications from existing technologies; and (ii) acquisition or licensing of biologicals and technologies for development of new products. Contract manufacturing of proteins and other biologicals for biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines is an example of significant new product application built from Meridian's existing expertise in manufacturing bulk antigens and reagents using cell culture techniques. This business will focus on contract manufacturing of materials that will be used in Phase I and II clinical trials. In July 2005 Meridian was awarded the exclusive global license for the Recombinant Parvovirus B19 vaccine technology from the National Institutes of Health (NIH). In 2006 Meridian completed the production of the Parvovirus B19 vaccine for the NIH and received clearance to initiate Phase I clinical trials with the material in Q1 of 2007. In 2007, Meridian completed manufacturing of a clinical infectious inoculum of respiratory syncytial virus (RSV) for Alnylam Pharmaceutical’s human clinical trials. Meridian is currently negotiating with several additional biopharmaceutical companies for the production of recombinant proteins for use in therapeutic agents and vaccines. These materials are intended to be used as "injectibles." As such, they will be produced under cGMP Regulations for Biologics and Human Drugs under the auspices of the FDA.Meridian expects that its Life Science operating segment will serve as a key platform for sourcing biologicals and technologies, by acquisition or license, for development of new products for all of Meridian's operating segments. One of Meridian's specific strategies in this area is to target biologicals that have commercial product applications across multiple markets, such as human diagnostics, veterinary diagnostics and therapeutics. This strategy is expected to leverage research and development resources as products can be developed with all three markets in mind, rather than on a market-by-market basis.The Life Science operating segment has targeted three primary market segments for its products and services: bulk biomedical reagents, drug and vaccine discovery, and drug and vaccine development. The customer base for bulk biomedical reagents is large and fragmented, and includes other diagnostic manufacturers as well as researchers in academia and the pharmaceutical and biotechnology industries. The market segments for drug and vaccine discovery and development are intended to be served via contract manufacturing in the protein production laboratory discussed above.